Heidenreich Paul A, Bozkurt Biykem, Aguilar David, Allen Larry A, Byun Joni J, Colvin Monica M, Deswal Anita, Drazner Mark H, Dunlay Shannon M, Evers Linda R, Fang James C, Fedson Savitri E, Fonarow Gregg C, Hayek Salim S, Hernandez Adrian F, Khazanie Prateeti, Kittleson Michelle M, Lee Christopher S, Link Mark S, Milano Carmelo A, Nnacheta Lorraine C, Sandhu Alexander T, Stevenson Lynne Warner, Vardeny Orly, Vest Amanda R, Yancy Clyde W
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1.
The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.
A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021.
Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.
《2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南》取代了《2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南》以及《2017年美国心脏病学会/美国心脏协会/美国心力衰竭学会对2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南的重点更新》。2022年指南旨在为临床医生提供以患者为中心的建议，以预防、诊断和管理心力衰竭患者。
于2020年5月至2020年12月进行了全面的文献检索，涵盖在MEDLINE（PubMed）、EMBASE、Cochrane协作网、医疗保健研究与质量局以及其他相关数据库中以英文发表的关于人类受试者的研究、综述和其他证据。还纳入了截至2021年9月发表的其他相关临床试验和研究。本指南与截至2021年12月发布的其他美国心脏协会/美国心脏病学会指南保持一致。
心力衰竭仍然是全球发病和死亡的主要原因。2022年心力衰竭指南基于当代证据为这些患者的治疗提供建议。这些建议提出了一种基于证据的方法来管理心力衰竭患者，旨在提高护理质量并符合患者利益。早期心力衰竭指南中的许多建议已根据新证据进行了更新，并且在有已发表数据支持时创建了新的建议。对于某些有高质量已发表经济分析的治疗方法，提供了价值声明。
